WO2014134830A1 - Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire - Google Patents

Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire Download PDF

Info

Publication number
WO2014134830A1
WO2014134830A1 PCT/CN2013/072367 CN2013072367W WO2014134830A1 WO 2014134830 A1 WO2014134830 A1 WO 2014134830A1 CN 2013072367 W CN2013072367 W CN 2013072367W WO 2014134830 A1 WO2014134830 A1 WO 2014134830A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
edible composition
food
group
Prior art date
Application number
PCT/CN2013/072367
Other languages
English (en)
Chinese (zh)
Inventor
黄璐
杨爽
汪小刚
张海峰
张思佳
朱江阳
熊周权
康辉
汪建
Original Assignee
深圳华大基因科技有限公司
武汉华大药业有限公司
华大基因（老挝）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳华大基因科技有限公司, 武汉华大药业有限公司, 华大基因（老挝）有限公司 filed Critical 深圳华大基因科技有限公司
Priority to PCT/CN2013/072367 priority Critical patent/WO2014134830A1/fr
Priority to CN201380073941.1A priority patent/CN105050427B/zh
Publication of WO2014134830A1 publication Critical patent/WO2014134830A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the invention belongs to the field of health foods, and in particular relates to an edible composition and a food containing the edible composition
  • the immune system in the human body is composed of immune organs and immune cells. It is our natural natural barrier. It not only protects against foreign bacteria and other harmful substances, but also eliminates cells that are aging, mutated, deteriorated or dead in the body. Keep your body healthy. Immunity is the ability of the human body to resist the invasion of external evils and maintain the stability of the internal environment. Immunity is low and vulnerable to disease. Improving human immunity is the basis for overcoming disease.
  • Microorganisms such as bacteria and fungi are widely found in the natural environment in which we live, and also in the body surface and body cavity of the human body. Under normal circumstances, these bacteria are generally harmless to the human body, and some of the bacteria are even beneficial. They form a complex interdependent and mutually constrained micro-ecological system with the human body and the external environment.
  • the intestinal flora is an important part of the intestinal defense barrier, and a balanced intestinal flora is important for human health.
  • the present invention is directed to solving at least some of the above technical problems or at least providing a useful commercial choice. To this end, it is an object of the present invention to provide an edible composition which simultaneously has a regulatory effect of improving gastrointestinal function and enhancing human immunity.
  • the present invention provides an edible composition comprising, according to an embodiment of the present invention, 40 to 120 parts by weight of Inca; 10 to 90 parts by weight Astragalus; 10 to 80 parts by weight of hydrazine; 30 to 100 parts by weight of inulin; 30 to 90 parts by weight of corn pollen; 10 to 90 parts by weight of slag leaves and 20 to 120 parts by weight of functional sugar.
  • Chinese medicines and food ingredients mainly include amino acids, polysaccharides, vitamins, various trace elements and other organic and inorganic substances.
  • these Chinese medicines and many components in foods promote the growth metabolism of bacteria, promote the proliferation of gastrointestinal probiotics, inhibit the growth of pathogenic bacteria, and play an important role in the intestinal flora.
  • probiotics can also promote the absorption and utilization of these traditional Chinese medicines and foods, improve the function of the human gastrointestinal tract, enhance the body's immunity, and enhance the body's ability to resist disease.
  • an edible composition composed of a mixture of Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves and Functional Sugar is improving.
  • the function of the gastrointestinal tract and the function of enhancing the immunity of the human body are obvious, and the combination of the components of the edible composition in improving the function of the gastrointestinal tract and enhancing the immunity of the human body is superior to the effect of the single component, and has obvious effects. Synergies.
  • Inca (P/lessiii vo/ b fc L.Jnca Peanut, sacha inchi) is a large vine, also known as Inca peanut, South American vine, Star vine, and Meito fruit.
  • the seeds are rich in oil, protein, amino acids, vitamin A, vitamin E and some other trace elements.
  • Inca oil contains extremely rich unsaturated fatty acids ( ⁇ -3, ⁇ -6, ⁇ - 9), as well as vitamins, strontium and protein, and the content of three unsaturated fatty acids is as high as 92% or more.
  • Inca fruit is rich in essential fatty acids a-linolenic acid, the mother of omega-3 unsaturated fatty acids, the most basic and primitive substance in the evolution of life.
  • (-Linolenic acid, as the core substance of life is one of the important components of human tissue cells. It is involved in the synthesis and metabolism of phospholipids in the human body, and is transformed into the vital activity factors DHA and sputum necessary for the body.
  • Astragalus membranaceus is the dry root of the leguminous plant Astragalus.
  • the plant is mainly distributed in the northeast, north and northwest of China.
  • the chemical constituents of Astragalus are mainly monosaccharides, polysaccharides, saponins, flavonoids, amino acids and trace elements.
  • Force, anti-fatigue, anti-mutation, liver protection, inhibition of osteoclasts can prevent the immunosuppressive effect of hydrocortisone, and can enhance the phagocytic function of macrophages and promote antibody synthesis; have detoxification effect, can strengthen normal
  • the heart contraction which has a strong heart effect on the failing heart, can dilate the blood vessels of the coronary vessels and kidneys and dilate the blood vessels at the peripheral end of the body.
  • It contains polysaccharides, glucose, protein, amino acids, organic acids, fats, lecithin, adenine, choline, ergosterol, various enzymes and potassium salts. It can enhance the body's immune function, diuretic effect, calming and protecting the liver, inhibiting the occurrence of ulcers, lowering blood sugar, and resisting radiation. It can also be used as an important therapeutic ingredient for glutinous cakes, glutinous rice cakes and alcoholics. It can be eaten regularly to moisturize the spleen, help digestion, and strengthen the body.
  • Inulin is mainly distributed in Compositae, with the highest content in chicory. Inulin is the highest quality, pure natural, soluble fructan mixture found by humans to date. Inulin was approved by the Ministry of Health as a new resource food in 2009. Inulin has the characteristics of low calorie, water solubility and the like, and enhances the proliferation of bifidobacteria, lowers blood sugar and blood lipids, restores gastrointestinal function, and enhances calcium absorption. Feeding inulin every day can greatly increase the number of beneficial bacteria in the colon, reducing pathogens and spoilage bacteria such as Salmonella, Listeria, Staphylococcus aureus, and coliforms.
  • the mechanism is that the inulin is not digested and absorbed, but directly enters the large intestine and is preferentially used by bifidobacteria to produce acetate and lactate, which lowers the pH value of the large intestine, thereby inhibiting the growth of harmful bacteria.
  • Corn is the third largest crop in China, and the northeast is the main producing area of corn in China.
  • the corn pollen resources are abundant. Corn pollen has high nutritional value, large individual size, large yield and easy harvesting. Corn pollen is rich in protein, sugar, amino acids, nucleic acids, vitamins and other nutrients. After the corn pollen is broken, it can separate and extract the active ingredients such as polysaccharides and flavonoids. It can promote the development of immune organs of the spleen, bones, lymph nodes and thymus, enhance the activity of immune cells, improve the body's ability to fight bacteria and viruses, and have anti-radiation and anti-cancer effects. It can enhance immunity, promote growth and development, lower blood pressure and other health care. Features.
  • corn pollen can provide a variety of nutrients needed by the human body, and it also has a good auxiliary effect for diseases caused by lack of certain nutrition. Therefore, corn pollen has a wide range of clinical applications and is a supplement to various diseases and a supplement to daily nutrition.
  • Corn pollen can be processed into health drinks such as oral liquid, pollen capsules, pollen beverages and pollen yoghurt, as well as functional foods such as pollen bread and pollen noodles.
  • Corn pollen is rich in vitamin B group substances, among which vitamin B1 can stimulate the production of digestive enzymes and help digestion; vitamin B6, minerals and methionine can treat intractable constipation and diarrhea; corn pollen also contains natural Antibiotics and growth-promoting substances can control the growth of coliforms and salmonella, repair the parts of gastrointestinal damage, and thus have magical effects on the treatment of gastric and duodenal ulcers and perforations.
  • the slag leaves are the rags of the genus Eucalyptus.
  • the leaves of Microcos paniculata. can be harvested all year round. They are usually picked in summer and autumn, and the stems are removed.
  • the slag leaves are light, slightly acidic, and flat. They have the effects of clearing heat and eliminating stagnation, dampness and yellowing, and phlegm. They are mainly used for colds, heatstroke, loss of appetite, indigestion, dampness and heat stagnation, abdominal pain, and less food. Diarrhea, damp heat, jaundice, etc.
  • the slag leaves contain alkaloids, organic acids, sugars, phenols and tannins. Since ancient times, the slag leaves have been widely used in the folks of Lingnan in China. Folk slag leaves are used as summer drinks, which have thirst-quenching and appetizing effects.
  • a preferred edible composition comprises: 70 to 110 parts by weight of Inca; 30 to 70 parts by weight of xanthine; 20 to 60 parts by weight of hydrazine; 50 to 80 parts by weight of inulin; ⁇ 80 parts by weight of corn pollen; 30 to 70 parts by weight of cloth slag leaves and 40 to 100 parts by weight of functional sugar.
  • the most preferred edible composition comprises: 90 parts by weight of Inca; 60 parts by weight Astragalus; 50 parts by weight of enamel; 70 parts by weight of inulin; 70 parts by weight of corn pollen; 50 parts by weight of cloth slag leaves and 70 parts by weight of functional sugar.
  • the type of functional sugar which can be used in the edible composition of the present invention is not particularly limited.
  • the functional sugar that can be employed is at least selected from the group consisting of konjac glucomannan, yeast glucan, chitooligosaccharide, oligofructose, galactooligosaccharide, xylooligosaccharide, and oligo-isomaltose.
  • konjac glucomannan yeast glucan
  • chitooligosaccharide oligofructose
  • galactooligosaccharide galactooligosaccharide
  • xylooligosaccharide oligo-isomaltose
  • Konjac glucomannan is a high molecular weight water soluble polysaccharide. China and Japan cultivated and consumed konjac since ancient times. In 1997, the US FDA approved konjac glucomannan as a food additive. On February 16, 1998, the Chinese Ministry of Health officially listed Konjac as the new food resource list for general food management. On November 4, 1998, the EU officially approved the use of konjac glucomannan in food. Since konjac glucomannan has many excellent properties, it is widely used as a food and beverage additive.
  • Yeast glucan is derived from Saccharomyces cerevisiae. It has a variety of physiological activities due to its special structure, and it has been widely used in the GRAS (usually considered safe) in the US FDA. In a variety of foods. In China, the Ministry of Health of the People's Republic of China 2010 No. 9 Announcement approved yeast glucan as a new resource food, enabling it to be used in various foods.
  • yeast glucan As a dietary fiber, yeast glucan can be decomposed by intestinal bacteria, promote gastrointestinal motility, stimulate the secretion of digestive juice, and have the function of assisting digestion; it can increase the peristalsis of the intestine and promote defecation, thus effectively preventing constipation; Absorption of calcium, magnesium and zinc by the intestines.
  • the unique ⁇ -(1 ⁇ 3) framework of yeast glucose has a strong immunomodulatory activity. Can significantly improve human immunity.
  • Chitosan oligosaccharide is a product of polymerization degree 2-10 after degradation of chitosan. Its water solubility is better than that of chitosan, and it is easily absorbed and utilized. The absorption rate of chitosan oligosaccharide in human body is nearly 100%, and the biological activity is more than chitosan. Stronger. It inhibits tumor cell growth, strengthens liver function, enhances immunity, prevents stomach ulcers, lowers blood pressure, blood sugar, blood lipids, cholesterol absorption and antibacterial effects.
  • Oligofructose is widely found in onions, honey, aloe vera and wheat plants, but its content is extremely low. At present, fructose transferase produced by Aspergillus can be used in sucrose to produce oligofructose on a large scale. Oligosaccharide fructose can selectively proliferate bifidobacteria, which is metabolized by bifidobacteria to produce acetic acid and lactic acid, which makes the intestinal tract acidic, inhibits the proliferation of harmful bacteria, and promotes intestinal peristalsis. Oligofructose also has many important physiological functions such as regulating human immunity and lowering blood lipids.
  • Oligogalactose is a functional oligosaccharide with natural properties.
  • the high temperature sterilization and the decomposition of human stomach acid lose their original characteristics.
  • the galactooligosaccharide can be effectively utilized by both Bifidobacterium bisporus and C. lactis.
  • Oligosaccharide is the only functional sugar that can be utilized by the eight beneficial bacteria in the human intestine, and can inhibit the growth and reproduction of harmful bacteria in the human intestine.
  • galacto-oligosaccharide has broad market prospects in China.
  • Xylo-oligosaccharide is one of the most potent varieties of proliferating bifidobacteria in polymeric sugars.
  • Organic acids Reduce the pH of the intestines, inhibit the growth of harmful bacteria, and proliferate the probiotics in the intestines.
  • the attached pathogenic bacteria can be excreted through the intestinal tract, thereby preventing the disease from clustering in the intestinal tract and achieving the purpose of preventing diarrhea, thereby achieving health care effects. .
  • the form of the edible composition is not particularly limited as long as it can be used for consumption.
  • the comestible composition may be in the form of a capsule, tablet, granule or granule.
  • the invention proposes a food product.
  • the food product comprises the edible composition described above.
  • the form of the food is not particularly limited as long as it can be used for eating.
  • the food product may be in the form of a capsule, a tablet, a granule or a granule.
  • the food provided by the present invention can be used as a health food, which can be made into a pharmaceutically acceptable capsule, tablet, or granule by a conventional process.
  • the invention proposes a method of preparing a food product.
  • the method comprises: providing the edible composition described above, wherein the Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves, and Functional Sugar are in a granular form;
  • the comestible composition is subjected to a molding process to obtain the food product.
  • the particles have a particle size of from 100 to 300 mesh.
  • the shaping process further comprises: forming the comestible composition in the form of a capsule, tablet, granule or granule.
  • the health food of the present invention is subjected to a safety evaluation test, including a mouse acute toxicity test, a mouse genotoxicity test, a rat 30-day feeding test, and the above test indicates: the health food of the present invention, the acute oral cavity of the mouse
  • the toxicity test is more than 10 g/kg_bw, which is safe and non-toxic.
  • the Ames test result is negative
  • the mouse bone marrow polychromatic erythrocyte micronucleus test result is negative
  • the mouse sperm abnormality test result is negative, indicating The product has no mutagenic effect;
  • the results of the 30-day feeding test in rats indicate that the health food of the present invention has been subjected to a 30-day feeding experiment in rats, and has important indexes such as overall health status, physiological and biochemical functions and organ histomorphology of the rats. No significant impact.
  • Table The health food soft capsule according to the invention is safe to take.
  • the health food of the invention has the function and effect of enhancing immunity, and the health food of the invention has better effect on enhancing immunity than the single component of astragalus, oligofructose, chitosan oligosaccharide and yeast dextran. Effect.
  • the experimental results of the health-improving function of the health food of the present invention showed that there was no significant difference in body weight, thymus/body weight ratio, and spleen/body weight ratio of each batch of mice. In the mouse antibody-producing cell assay, the serum hemolysin assay, and the mouse carbon clearance assay, the results were significantly different.
  • Bifidobacteria are representative of beneficial bacteria, can inhibit the growth of harmful bacteria, and maintain the normal micro-ecological environment in the intestine. Increasing the number of bifidobacteria in the human gut can significantly improve the gastrointestinal function and health of the human body.
  • the animal experiment for regulating the function of the intestinal flora by the health food of the present invention, and the human food experiment for regulating the function of the intestinal flora can be seen that the health food of the present invention has the function of regulating the intestinal flora.
  • the present invention can significantly stimulate the growth and increase of the number of beneficial bacteria (such as bifidobacteria) in the human intestinal tract, and significantly reduce the number of harmful bacteria such as Clostridium perfringens.
  • the number of Bifidobacteria, Enterobacteriaceae, and the number of Clostridium perfringens in the human intestinal tract after taking Inca soft capsules were lower than those after taking Inca fruit oil and taking Xylooligosaccharides.
  • the effect of the subject after the capsule is more obvious, that is, the health care function of the health food of the present invention is superior to the effect of the single component.
  • the present invention has the function of improving gastrointestinal function, and can function as a laxative and prevent constipation, and no adverse reaction is observed during the administration.
  • the invention provides the use of the above edible composition in the preparation of a formulation.
  • any edible preparation can be prepared by using the above edible composition, for example, a pharmaceutically acceptable dosage form such as a capsule, a soft capsule, a tablet, or a granule can be prepared.
  • the above preparation can be used for improving gastrointestinal function and enhancing human immunity and the like.
  • a dosage form can be prepared by using the above edible composition for exerting its function of improving gastrointestinal function, enhancing human immunity, and the like.
  • All the raw materials in the health food according to the present invention are natural, natural, safe and reliable, and the raw materials are widely available.
  • the compatibility of the prescriptions is scientific and reasonable, the curative effect is exact, the preparation process is simple, and the storage and application are safe. Production costs are low.
  • a health food consisting of a mixture of Inca, Astragalus, Poria, Inulin, Corn Pollen, Cloth Leaves and Functional Sugar,
  • the combination of functions and functions has obvious health care functions and synergistic effects for simultaneously improving the gastrointestinal tract and enhancing human immunity, and the combined effect of the invention in improving gastrointestinal function and enhancing human immunity is better than single The effect of the ingredients.
  • the health food of the invention not only improves the human immunity, but also improves the distribution of the intestinal flora of the human body, significantly stimulates the growth and increase of the number of beneficial bacteria (such as bifidobacteria) in the human intestinal tract, and reduces the harmfulness in the intestinal tract.
  • Bacteria The number of Clostridium perfringens plays a bacteriostatic effect, and at the same time achieves the health benefits of enhancing immunity, regulating intestinal flora, laxative, and preventing constipation.
  • the raw materials are mixed and pulverized into fine powder of 100-230 mesh, which is favorable for uniform dispersion of the active ingredients in the raw materials, and is convenient for absorption in the gastrointestinal tract of the human body.
  • the use of Inca fruit oil as a dispersing agent for soft capsules is advantageous for soft capsule molding, and the soft capsule dosage form is also advantageous for uniformly dispersing other active ingredients in the oil to facilitate absorption by the human body.
  • the health food of the invention has obvious efficacy, good safety, stable quality, long-term preservation of the product, and provides a new choice for daily health care.
  • Example 1-12 The health food formula of the present invention
  • Example 1 Example 2
  • Example 3 Example 4
  • Example 5 Case 6
  • Case 7 Case 8
  • Case 9 Case 10
  • Example 12 Inca 40 70 70 90 120 90 110 120 100 90 110 90 Astragalus 90 50 70 60 60 50 10 80 60 60 30 70 ⁇ 70 60 80 50 50 10 80 70 70 50 20 70 Inulin 40 80 60 70 50 80 100 30 50 70 90 50 50 Corn pollen 60 30 60 70 90 80 50 60 90 70 70 60 slag leaves 40 70 90 50 10 60 60 60 40 50 70 50 Konjac glucomannan 100 25 30
  • Yeast dextran 80 —— 30 70 25 ——
  • Redundant sugar 70 30 60 oligofructose 40 40 oligogalactose 40 20 40 20 xylooligo 60 20
  • Cystic sac According to the above table, the components of the health food according to the present invention can be made into capsules, tablets, or granules in pharmacy by a conventional process.
  • Example 4 For the health food granules described in Example 4 (hereinafter referred to as Inca granules), the preparation process is as follows:
  • Health care function regulate intestinal flora, enhance immunity
  • Suitable for people those with intestinal dysfunction and those with low immunity
  • Storage method sealed, kept in a cool dry place
  • Inca soft capsule For the health food soft capsule (hereinafter referred to as Inca soft capsule) described in Example 10, the preparation process is as follows:
  • the unqualified soft capsules such as the appearance and the joints are sorted and discarded, and the selected qualified soft capsules are packaged in the form of bottles or blister sheets, that is, the finished products (referred to as Inca soft capsules).
  • Health care function regulate intestinal flora, enhance immunity
  • Storage method sealed, kept in a cool dry place
  • Example 13 Determination of acute toxicity by oral administration to rats
  • Acute toxicity tests were performed using 6-week-old SD rats without specific pathogens (SPF).
  • Example 4 The health food prepared in Example 4 was suspended in a 0.5% methylcellulose solution, and orally administered to 5 SD rats in each group at a dose of lg/kg, 5 g/kg, and 10 g/kg, respectively. Rats were tested for death, clinical symptoms, and weight changes, and blood tests and blood biochemical tests were performed. At autopsy, any abnormalities in the gastrointestinal tissue of the chest and abdomen were visually examined.
  • Example 14 Study of enhancing immunity function
  • mice BALB/C 1 month old secondary mice, male and female, weighing 20 ⁇ 2g, in good health, provided by Experimental Animal Center of Wuhan University Medical College, production license number: SCXK (E) 2008-0004. Each batch of animals was randomized.
  • the Indo-Chong granule prepared in Example 6 was used.
  • the recommended dose was 250 mg/kg.BW (body weight) per day, and 0.5, 1, and 2 times of the mice were recommended as low dose group C125 mg/kg. .BW), medium dose group (250 mg/kg. BW), high dose group (500 mg/kg. BW).
  • the positive control group 1 is the Astragalus polysaccharide capsule (the main raw materials: Astragalus, oligo-isomalt, Inner Mongolia Shuangqi Pharmaceutical Co., Ltd., Guoshijianzi G20040082),
  • Positive control group 2 is oligofructose oral solution (main raw materials: oligofructose, Zhuhai Shengyuan Biotechnology Co., Ltd., Guoshijianzi G20050336),
  • the positive control group 3 was chitosan oligosaccharide capsules (main raw materials: chitosan oligosaccharide, Xiamen Lanwan Technology Co., Ltd., Guoshijianzi G20110158),
  • the positive control group 4 is yeast glucan capsule (main raw material: yeast glucan, Nanjing Dayuan Beauty Health Care Co., Ltd. Division, Guoshijianzi G20110445).
  • SRBC sheep red blood cells
  • Hank's solution Hank's solution
  • guinea pig serum ink.
  • NaCl 80.00g
  • KC1 4.00g
  • KH 2 PO 4 0.60g
  • 0.4% phenol red liquid 50.00mL
  • double distilled water plus constant volume to lOOmL autoclaved at 115 °C for 15 min, stored frozen.
  • the test was performed by gavage.
  • the stomach was administered once a day, and the blank control group was filled with the same volume of distilled water.
  • Each group of mice was continuously administered with the test substance for 30 days, and each index was measured.
  • mice 2.1 Effects on body weight, thymus/body weight, spleen/body weight of mice
  • mice were sacrificed by cervical dislocation 30 days later and weighed.
  • the thymus and spleen were taken, and the thymus and spleen weights were weighed separately, and the thymus/body weight value and the spleen/body weight value were measured.
  • mice were immunized by intraperitoneal injection of 0.2 mL of 2% (v/v) SRBC. 5 days after immunization, the mouse spleen is made to take a cell concentration of spleen cells was 5x l0 6 cells / mL. Dissolve the agarose to make a 1% solution, incubate in a 48 ° C water bath, mix with an equal amount of 2 times the concentration of Hank's solution, and dispense into a small tube, 0.5 mL per tube. Add 0.05 mL of 10% SRBC and O.OlmL spleen cell suspension, mix quickly and pour onto the slide. Incubate for 1 h in a 37 ° C incubator, add complement (guinea pig serum) to the slide trough, and incubate for 1.5 h. Count plaques.
  • complement guinea pig serum
  • mice were immunized by intraperitoneal injection of 0.2 mL of 2% (v/v) SRBC. After 5 days of immunization, the eyeballs were taken from the centrifuge tube, placed for 1 h, centrifuged at 3000 rpm for 5 minutes, and serum was collected. The serum was diluted 400-fold with physiological saline, and diluted mouse serum 1.0 mL, 10% (v/v) SRBC 0.5 mL, and complement (diluted with physiological saline 1:10) 1.00 mL were sequentially added. A serum-free control tube replaced with physiological saline was also provided.
  • the reaction was stopped at 0 ° C for 30 minutes, and centrifuged at 3000 rpm for 5 minutes. The supernatant was taken to 1.0 mL, and the optical density value was measured at a wavelength of 540 nm of a spectrophotometer.
  • Each mouse was injected with 4 times diluted ink in the tail vein, 0.1 mL/10 g body weight. Time is counted immediately after the ink is injected. 0.02 mL of blood was taken to 2.0 mL of 0.1% Na 2 C0 3 solution (ie, lg/L) at 1 minute and 10 minutes after injecting the ink, respectively. The optical density value was measured at a wavelength of 600 nm using a Na 2 CO 3 solution as a control. The liver and spleen were weighed. The phagocytic index ((X) is used to indicate the ability of the mouse to clear the carbon.
  • mice The effects of each test substance on the body weight, thymus/body weight ratio, and spleen/body weight ratio of the mice are shown in Tables 2, 3 and 4.
  • the antibody-producing cell (PFC) test results are shown in Table 5.
  • Group Ll amount (mg/kg 'bw) Number of animals (only) Number of antibody-producing cells (x ⁇ s)
  • P value blank control group 0 12 72 ⁇ 22 - Positive control group 1 1 capsule 12 89 ⁇ 19 0.0452
  • Positive control 2 groups 0.5mL 12 83 ⁇ 23 0.1954
  • positive control 3 groups 1 capsule 12 83 ⁇ 21 0.2019 positive control 4
  • Dosage group 500 12 90 ⁇ 21 0.0687 It can be seen from Table 5 that after oral administration of different doses of the test substance to the mice for 30 days, compared with the blank control group, the positive control group
  • the phagocytosis ability of the cells was significantly different (P ⁇ 0.01).
  • the low-dose group, the positive control group 1 and the positive control group 2 had significant differences in the phagocytic ability of mouse macrophages (P ⁇ 0.05), and the other groups were small.
  • the mouse carbon clearance ability has no effect. This indicates that the health food of the present embodiment has an effect of enhancing the phagocytic function of mononuclear macrophages, and can enhance non-specific immune function of mice.
  • the results of experiments before and after improving the immunity function of the health food of the present example showed that there was no significant difference in body weight, thymus/weight ratio, and spleen/body weight ratio of each batch of mice.
  • the health food of the present embodiment can be considered to have the function and effect of enhancing immunity, and the health food of the present embodiment is superior to the single component of jaundice, oligofructose, chitooligosaccharide, and yeast.
  • the effect of the glycan is not limited to the human milk, the serum hemolysin assay, and the mouse carbon clearance assay.
  • the health food granules (hereinafter referred to as Inca granules) used in the present embodiment were prepared in the same manner as in Example 4, and were packed in 5 g/bag aluminum foil.
  • the recommended eating method was 2 times a day, 1 bag each time.
  • the health food soft capsule (hereinafter referred to as Inca soft capsule) used in the present embodiment is prepared by the method of Example 10, and has a specification of 1.0 g/granule.
  • the recommended eating method is 3 times a day, 3 capsules each time.
  • the human food test experiment added two positive control groups, which were:
  • Positive control group 1 Inca fruit oil (from Huada Gene (Laos) Co., Ltd., batch number 20120301), 2 times a day, 5mL each time;
  • Positive control group 2 xylooligosaccharide capsule (Shandong Longli Biotechnology Co., Ltd., Guoshijianzi G20041284), 2 times a day, 3 capsules each time;
  • Bifidobacterium BBL medium, 37 °C, animal experiment 72h anaerobic culture, human food test 48h anaerobic culture; Lactobacillus: LBS medium, 37 ° C, 48h culture;
  • EMB medium 37 ° C, 24 h culture
  • Enterococcus sodium azide - crystal violet - esculin culture medium, 37 ° C, animal experiment 24 h culture, human trial experiment 48 h + Li Guan.
  • Clostridium perfringens TSC medium, 37 ° C, 24 h anaerobic culture.
  • mice 50 male mice were randomly divided into 5 groups, 10 in each group, of which 1 group was the normal control group, and the other 4 groups were given lincomycin hydrochloride.
  • the dosage was 60 mg/10g_bw for 3 days.
  • the mice developed dysbacteriosis, and one group was randomly selected to be administered with normal saline as a natural recovery group, and the other three groups were administered with the granules of the present example.
  • the mouse feces were aseptically taken to detect the number of intestinal flora, and the changes of Bifidobacterium, Lactobacillus, Enterococcus, Enterobacter, Clostridium perfringens before and after the experiment were compared. .
  • the subjects were randomly divided into 3 groups, and the subjects' faeces were aseptically taken before the subjects were tested, and the number of intestinal flora was examined.
  • the first group of subjects took the Inca soft capsule of the present example, 3 times a day, 3 times each time, for 7 days;
  • the second group of subjects took the positive control group 1 of Inca fruit oil, 2 times a day, 5mL each time;
  • the third group of subjects took the positive control group 2 xylooligosaccharide capsules, 2 times a day, 3 capsules each time;
  • the number of bifidobacteria increased significantly, the difference was significant ( ⁇ .05), and the number of lactobacilli increased significantly, and the difference was extremely significant ( ⁇ 0.01).
  • the number of Enterococcus and Clostridium perfringens was significantly increased in the middle dose group, the difference was significant ( ⁇ 0.05), and the number of Enterobacteriaceae was significantly increased.
  • the difference was extremely significant ( ⁇ 0.01).
  • the number of bifidobacteria and lactobacilli increased significantly, and the difference was extremely significant ( ⁇ 0.01).
  • the number of enterococci and Clostridium perfringens increased significantly, and the difference was significant.
  • Bifidobacteria are representative of beneficial bacteria, can inhibit the growth of harmful bacteria, and maintain the normal micro-ecological environment in the intestine. Increasing the number of bifidobacteria in the human gut can significantly improve the gastrointestinal function and health of the human body.
  • the animal experiment of regulating the function of the intestinal flora by the above-mentioned Inka soft capsule and the human food test experiment of regulating the function of the intestinal flora can be seen that the health food of the embodiment has the function of regulating the intestinal flora, and the invention can significantly stimulate the human intestine
  • the number of beneficial bacteria in the tract, Bifidobacteria, Enterobacter, and the number of harmful bacteria Clostridium perfringens were significantly reduced.
  • the number of Bifidobacteria, Enterobacteriaceae, and the number of Clostridium perfringens in the human intestinal tract after taking Inca soft capsules were lower than those after taking Inca fruit oil and taking Xylooligosaccharides.
  • the effect of the subject after the capsule is more obvious, that is, the health care function of the health food of the present invention is superior to the effect of the single component.
  • the present embodiment adopts the Indo-Chong agent (hereinafter referred to as Inca granule) prepared in the fourth embodiment.
  • mild constipation means 2-3 days of bowel movements
  • moderate constipation means 3-6 days of bowel movements
  • severe constipation means more than 7 days of bowel movements or relies on laxatives for defecation, once or twice a day.
  • Patients with mild constipation took Inca granules for 7 days, taking 2 bags a day for the first three days, and then taking 1 bag every day for four days.
  • Patients with moderate constipation took Inca granules for 7 days, taking 4 bags a day for the first three days, and then taking 2 bags a day for four days, brewing in warm water.
  • Patients with severe constipation took Inca granules for 7 days, taking 6 bags a day for the first three days, and then 3 bags a day for four days.
  • the product has the function of improving the function of the gastrointestinal tract, and can function as a laxative and constipation, and no adverse reaction is observed during the administration.
  • the description of the terms “one embodiment”, “some embodiments”, “example”, “specific example”, or “some examples” and the like means a specific feature described in connection with the embodiment or example.
  • a structure, material or feature is included in at least one embodiment or example of the invention.
  • the schematic representation of the above terms does not necessarily mean the same embodiment or example.
  • the particular features, structures, materials, or characteristics described may be combined in a suitable manner in any one or more embodiments or examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention porte sur une composition comestible, sur un produit alimentaire la comprenant et sur un procédé de préparation pour le produit alimentaire. La composition comestible comprend : 120 parties en poids de Sacha inchi, 10-90 parties en poids d'Astragalus, 10-80 parties en poids de poria, 30-100 parties en poids d'inuline, 30-90 parties en poids de pollen de maïs, 10-90 parties en poids de Strophanthus divaricatus et 20-120 parties en poids d'un sucre fonctionnel.
PCT/CN2013/072367 2013-03-08 2013-03-08 Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire WO2014134830A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072367 WO2014134830A1 (fr) 2013-03-08 2013-03-08 Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire
CN201380073941.1A CN105050427B (zh) 2013-03-08 2013-03-08 可食用组合物以及包含其的食品、该食品的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/072367 WO2014134830A1 (fr) 2013-03-08 2013-03-08 Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire

Publications (1)

Publication Number Publication Date
WO2014134830A1 true WO2014134830A1 (fr) 2014-09-12

Family

ID=51490592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/072367 WO2014134830A1 (fr) 2013-03-08 2013-03-08 Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire

Country Status (2)

Country Link
CN (1) CN105050427B (fr)
WO (1) WO2014134830A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078088A1 (fr) * 2014-11-21 2016-05-26 深圳华大基因科技有限公司 Utilisation d'huile sacha inchi dans la régulation de la flore du tractus intestinal d'animaux

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106190768A (zh) * 2016-07-22 2016-12-07 重庆修贤生物科技有限公司 低聚果糖和壳寡糖在醋制品中的应用
CN117122002A (zh) * 2023-09-11 2023-11-28 辅农(廊坊)生物科技有限公司 一种改善肠道菌群的固体饮料及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1927356A (zh) * 2006-09-08 2007-03-14 陈大刚 一种增强人体免疫力、抗氧化的功能型保健食品
CN101999578A (zh) * 2010-10-29 2011-04-06 无限极（中国）有限公司 一种适合儿童食用的具有增强免疫力功能的保健食品
CN102228255A (zh) * 2011-05-18 2011-11-02 广州智享生物科技有限公司 可缓解精神压力和抗抑郁的营养冲剂及制备方法
CN102949644A (zh) * 2012-11-14 2013-03-06 西安福安创意咨询有限责任公司 治疗肺气肿、哮喘缓解、慢性支气管炎的保健品片剂及制备

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101999652B (zh) * 2010-10-27 2012-06-27 中国科学院西双版纳热带植物园 一种具有降血脂功能的保健食品及其制备方法
CN101982197B (zh) * 2010-10-27 2012-07-25 中国科学院西双版纳热带植物园 一种南美油藤多肽口服液
CN102988744A (zh) * 2011-09-08 2013-03-27 姜永芳 一种治疗慢性胃炎的药物组合物及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1927356A (zh) * 2006-09-08 2007-03-14 陈大刚 一种增强人体免疫力、抗氧化的功能型保健食品
CN101999578A (zh) * 2010-10-29 2011-04-06 无限极（中国）有限公司 一种适合儿童食用的具有增强免疫力功能的保健食品
CN102228255A (zh) * 2011-05-18 2011-11-02 广州智享生物科技有限公司 可缓解精神压力和抗抑郁的营养冲剂及制备方法
CN102949644A (zh) * 2012-11-14 2013-03-06 西安福安创意咨询有限责任公司 治疗肺气肿、哮喘缓解、慢性支气管炎的保健品片剂及制备

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI, HONGFEI ET AL.: "zenglli4 kang4pi2lao2 bao3jian4 shan4shi2 pei4fangl guillv4 he2 penglren4 te4dian3 yan2jiu1.", FOOD SCIENCE, vol. 26, no. 9, 2005, pages 476 - 481 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078088A1 (fr) * 2014-11-21 2016-05-26 深圳华大基因科技有限公司 Utilisation d'huile sacha inchi dans la régulation de la flore du tractus intestinal d'animaux

Also Published As

Publication number Publication date
CN105050427A (zh) 2015-11-11
CN105050427B (zh) 2017-07-18

Similar Documents

Publication Publication Date Title
JP6271571B2 (ja) 腸内微生物叢の平衡を保つための組成物、該組成物の製法、および、該組成物の利用
ES2886951T3 (es) Composición para su uso en la modulación de la microbiota
CN106954847A (zh) 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂
CN107319525A (zh) 一种减肥减脂专用型临床营养配方及其制备方法
WO2022016774A1 (fr) Composition utile pour réguler le tractus intestinal, favoriser la digestion et atténuer la constipation, et son procédé de préparation
KR101738912B1 (ko) 비만억제 및 다이어트 조성물
CN104366480A (zh) 一种减肥降脂营养代餐粉及其制备方法
CN112741320A (zh) 一种减肥组合物及其制备方法和应用
CN108719984B (zh) 一种针对痛风人群的代餐营养棒及其制备方法
CN106723087A (zh) 一种含海带膳食纤维的片剂及其制备方法
CN105105116A (zh) 具有缓解体力疲劳和增强免疫力的保健食品及其制备方法
CN106690331A (zh) 一种海带膳食纤维颗粒及其制备方法
CN106578093A (zh) 一种创伤、感染、手术及其它应激状态专用型临床营养配方及其制备方法
CN112021564B (zh) 一种用于养护胃肠的组合物及其制备方法和应用
CN109329930A (zh) 一种促进尿酸降低的组合物及其制备方法
CN106723015A (zh) 一种具有抗疲劳和抗氧化功能的保健食品及其制备工艺
CN111543605A (zh) 一种四高或肥胖人群用综合营养粉
CN106418501A (zh) 一种具有减肥功能的保健食品
CN110710660A (zh) 含有苦瓜粉的降低血糖组合物及膳食补充剂
WO2014134830A1 (fr) Composition comestible, produit alimentaire la comprenant et procédé de préparation pour le produit alimentaire
KR102000170B1 (ko) 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품
CN103920140B (zh) 一种人用降糖减肥降脂复方制剂
CN108887688A (zh) 一种多样性的膳食纤维及其制备方法
CN114259044A (zh) 一种决明子火麻仁复合发酵物、功能性果蔬酵素果冻及其制备方法
CN116268414A (zh) 一种改善胃肠道功能、防治便秘的组合物及其用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380073941.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13877051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13877051

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26-01-2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13877051

Country of ref document: EP

Kind code of ref document: A1